FUDR为主方案治疗晚期非小细胞肺癌的研究  

The efficacy and toxicity of the FUDR-based regimen in the treatment of advanced non-small cell lung cancer

作　　者：王淑琴[1] 刘巍[1] 王玉华[1] 翟宝娥[1] 

机构地区：[1]河北医科大学四院肿瘤科,石家庄050011

出　　处：《中国肺癌杂志》2002年第4期290-292,共3页Chinese Journal of Lung Cancer

摘　　要：目的　探讨氟脲脱氧核苷 (floxuridine ,FUDR ,氟苷 )为主方案治疗晚期非小细胞肺癌的疗效和毒性。方法　A组 (观察组 ) 5 0例 ,接受L/FUDR EP方案治疗 ;B组 (对照组 ) 42例 ,接受L/FEP方案治疗。每组均行 3程化疗方评价疗效。结果　A、B两组疗效分别为 40 .0 % (2 0 / 5 0 )及 3 8.1% (16/ 42 ) (P >0 .0 5 )。A组骨髓抑制、消化道反应、脱发、局部静脉炎发生率低于B组 (P <0 .0 1)。结论　FUDR为主方案治疗晚期NSCLC疗效确切 ,毒性较 5 FU低 ,值得临床推广应用。Objective To evaluate the efficacy and toxicity of the FUDR based regimen in the treatment of advanced non small cell lung cancer. Methods Fifty patients in group A received the L/FUDR EP regimen, while 42 patients in group B were given the L/FEP regimen. The response and toxicity were evaluated after three courses of treatment.Results The therapeutic response of group A and group B were 40.0% and 38.1% respectively (P>0.05). The toxicities such as marrow inhibition, gastrointestinal symptoms, alopecia and local phlebitis were remarkably lower in group A than those of group B (P<0.01). Conclusion The FUDR based regimen is effective to the advanced NSCLC, and its toxicity is lower than 5 FU.

关 键 词：FUDR 化学疗法 毒副反应 临床研究 晚期 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]